NASDAQ: TVRDTvardi Therapeutics Inc Stock
$24.61-0.60 (-2.38%)
Updated Jun 27, 2025
TVRD Price
$24.61
Fair Value Price
$2.41
Market Cap
$230.37M
52 Week Low
$8.13
52 Week High
$34.31
P/E
-0.82x
P/B
-28.54x
P/S
3.06x
PEG
N/A
Dividend Yield
N/A
Revenue
$7.57M
Earnings
-$45.08M
Gross Margin
100%
Operating Margin
-477.04%
Profit Margin
-595.4%
Debt to Equity
-5.82
Operating Cash Flow
-$35M
Beta
0.98
Next Earnings
Aug 12, 2025
Ex-Dividend
N/A
Next Dividend
N/A
TVRD Overview
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TVRD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important TVRD news, forecast changes, insider trades & much more!
TVRD News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TVRD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TVRD ($24.61) is overvalued by 920.97% relative to our estimate of its Fair Value price of $2.41 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TVRD ($24.61) is not significantly undervalued (920.97%) relative to our estimate of its Fair Value price of $2.41 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TVRD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TVRD due diligence checks available for Premium users.
Valuation
TVRD fair value
Fair Value of TVRD stock based on Discounted Cash Flow (DCF)
Price
$24.61
Fair Value
$2.41
Overvalued by
920.97%
TVRD ($24.61) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TVRD ($24.61) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TVRD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TVRD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.82x
Industry
-117.68x
Market
32.24x
TVRD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-28.54x
Industry
4.43x
TVRD's financial health
Profit margin
Revenue
$2.6M
Net Income
-$4.9M
Profit Margin
-191%
TVRD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TVRD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$38.9M
Liabilities
$47.0M
Debt to equity
-5.82
TVRD's short-term assets ($38.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TVRD's long-term liabilities ($45.82M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TVRD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TVRD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.7M
Investing
$0.0
Financing
$1.0M
TVRD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TVRD vs Biotech Stocks
Tvardi Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.